Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study

2016 ◽  
Vol 117 (11) ◽  
pp. 1703-1713 ◽  
Author(s):  
Gennaro Giustino ◽  
Ajay J. Kirtane ◽  
Philippe Généreux ◽  
Usman Baber ◽  
Bernhard Witzenbichler ◽  
...  
Keyword(s):  
Platelet Count ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Platelet Reactivity ◽  
Bleeding Risk ◽  
Drug Eluting Stents ◽  
Drug Eluting

Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study

2016 ◽  
Vol 117 (12) ◽  
pp. 1877-1883 ◽  
Author(s):  
Gennaro Giustino ◽  
Ajay J. Kirtane ◽  
Usman Baber ◽  
Philippe Généreux ◽  
Bernhard Witzenbichler ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Platelet Reactivity ◽  
Bleeding Risk ◽  
Drug Eluting Stents ◽  
Drug Eluting

Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents

2011 ◽  
Vol 27 (5) ◽  
pp. 480-485 ◽  
Author(s):  
Takahide Arai ◽  
Akio Kawamura ◽  
Yumiko Matsubara ◽  
Kenji Yokoyama ◽  
Yasuo Ikeda ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Platelet Reactivity ◽  
Drug Eluting Stents ◽  
Drug Eluting

scholarly journals COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?

2021 ◽  
Author(s):  
Anne Cornelissen ◽  
Atsushi Sakamoto ◽  
Yu Sato ◽  
Rika Kawakami ◽  
Masayuki Mori ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Bare Metal Stents ◽  
Bleeding Risk ◽  
Coronary Stent ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Preclinical Studies ◽  
Coronary Artery Stent ◽  
Drug Eluting

Major advances have been made in coronary artery stent technology over the last decades. Drug-eluting stents reduced in-stent restenosis and have shown better outcomes compared with bare metal stents, yet some limitations still exist to their use. Because they delay healing of the vessel wall, longer dual antiplatelet therapy is mandatory to mitigate against stent thrombosis and this limitation is most concerning in subjects at high risk for bleeding. The COBRA PzF nanocoated coronary stent has been associated with accelerated endothelialization relative to drug-eluting stents, reduced inflammation and thromboresistance in preclinical studies, suggesting more flexible dual antiplatelet therapy requirement with potential benefits especially in those at high bleeding risk. Here, we discuss the significance of COBRA PzF in light of recent experimental and clinical studies.

scholarly journals SHORT VERSUS LONG DURATION OF DUAL ANTIPLATELET THERAPY AFTER SECOND GENERATION DRUG-ELUTING STENTS IMPLANTATION IN DIABETICS

2021 ◽  
Vol 77 (18) ◽  
pp. 129
Author(s):  
Manesh Kumar Gangwani ◽  
Abeer Aziz ◽  
Shazib Sagheer ◽  
Priyanka Ahuja ◽  
Wade Lee-Smith ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Second Generation ◽  
Dual Antiplatelet Therapy ◽  
Drug Eluting Stents ◽  
Long Duration ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document